FSCN1是通过单细胞和散装RNA测序揭示的动脉样硬化潜在治疗标

Lili Zhang1, Han Jiang1, Lihua Li2

  • 1Department of Cardiology, Affiliated Hospital of Jiangsu University, Institute Cardiovascular Disease of Jiangsu University, Zhenjiang, 212001, People's Republic of China.

PubMed
概括

氨酸组合蛋白1 (FSCN1) 在动脉样硬化 (AS) 中升高,并与疾病风险增加有关. 减少内皮细胞中的FSCN1可能通过降低热和增强迁移来治疗AS.